EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessment of intrathecal therapy in the treatment of familial haemophagocytic lymphohistiocytosis

Katarina Zivkovic, Elisabet Bergsten, Maurizio Aricó, Itziar Astigarraga, Eiichi Ishii, Stephan Ladisch, Kai Lehmberg, Milen Minkov, Vasanta Nanduri, Jan-Inge Henter iD

British Journal of Haematology · 2026-02 · 208 (2) · 705-710

DOI: 10.1111/bjh.70251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 16.11.2025. Verfasst von Katarina Zivkovic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancerfonden, Insamlingsstiftelsen Cancer- och Allergifonden, Barncancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

= 1.0). This study has several limitations, especially regarding patient selection and confounding factors. IT treatment was not randomized, and due to a lack of data on clinical neu­ rological alterations at 2 weeks, as well as incomplete CSF data in many cases, it was not possible to determine which patients met the criteria for recommended IT therapy; ‘pro­ gressive neurological symptoms during the first 2 weeks or an abnormal cerebrospinal fluid value at onset that had not improved after 2 weeks’. Therefore, an indication bias is possible, and the absence of outcome differences could be the case of an effective treatment being given to a higher risk group of patients. Additionally, the rate of missing CSF data is a limitation, although information on neurological alterations, the main focus of the study, was mostly com­ plete at onset (78/78, 100%) and follow­ up (74/78, 95%). Furthermore, assessing neurological alterations, especially psychomotor retardation, is difficult in severely ill young children and is relevant here, because most patients were younger than 1 year at diagnosis. Finally, the multicentre design increases the risk of inconsistent neurological eval­ uations across centres. In conclusion, the data do not support a higher rate of normalization of neurological alterations in already symp­ tomatic FHL patients, nor less CNS involvement at 2 months follow­ up within the IT group. This lack of apparent clinical efficacy raises the question of whether IT therapy should be recommended for treating FHL. Our findings emphasize the need for further research, such as prospective clinical stud­ ies, animal studies and collaborative data analyses, to clarify the role of intrathecal therapy in FHL and to develop data­ driven recommendations.

Schlagwörter

Stichwörter der Autor:innen

Haemophagocytic lymphohistiocytosiscentral nervous systemintrathecal therapylong‐term complications

Autor:innen und Institutionen

  • Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Pediatrics, Azienda Sanitaria Locale Pescara, Pescara, Italy.
  • Department of Pediatrics, Hospital Universitario Cruces, Biobizkaia Health Research Institute, University of the Basque Country UPV/EHU, Barakaldo, Spain.
  • Imabari City Medical Association General Hospital, Imabari, Ehime, Japan.
  • Center for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, DC, USA.
  • Division of Pediatric Stem Cell Transplantation and Immunology, Department of Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany.

ORCID-Profile: Jan-Inge Henter

Förderung

  • Cancerfonden
  • Insamlingsstiftelsen Cancer- och Allergifonden
  • Barncancerfonden
  • Stockholm läns landsting

Zitieren

APA

Zivkovic, K., Bergsten, E., Aricó, M., Astigarraga, I., Ishii, E., Ladisch, S., Lehmberg, K., Minkov, M., Nanduri, V., & Henter, J. I. (2026). Assessment of intrathecal therapy in the treatment of familial haemophagocytic lymphohistiocytosis. British Journal of Haematology, 208(2), 705-710. https://doi.org/10.1111/bjh.70251

Vancouver

Zivkovic K, Bergsten E, Aricó M, Astigarraga I, Ishii E, Ladisch S, et al. Assessment of intrathecal therapy in the treatment of familial haemophagocytic lymphohistiocytosis. British Journal of Haematology. 2026;208(2):705-710. doi:10.1111/bjh.70251

BibTeX
@article{Zivkovic2026,
  author = {Zivkovic, Katarina and Bergsten, Elisabet and Aricó, Maurizio and Astigarraga, Itziar and Ishii, Eiichi and Ladisch, Stephan and Lehmberg, Kai and Minkov, Milen and Nanduri, Vasanta and Henter, Jan-Inge},
  title = {Assessment of intrathecal therapy in the treatment of familial haemophagocytic lymphohistiocytosis},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {2},
  pages = {705--710},
  doi = {10.1111/bjh.70251}
}
Kostenlos starten →